Department of Endocrinology, Amsterdam Movement Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam Gastroenterology Endocrinology & Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
J Clin Endocrinol Metab. 2022 Jan 18;107(2):e458-e466. doi: 10.1210/clinem/dgab741.
In trans women, hormone treatment induces feminization; however, the degree of feminization varies from person to person. A possible contributing factor could be estrone, a weak estrogen that interferes with the estrogen receptor.
We assessed whether estrone is involved in feminization induced by hormone treatment.
This prospective cohort study, with follow-up of 1 year, included 212 adult trans women at a gender identity clinic, who were starting gender-affirming hormone treatment between July 2017 and December 2019, median age 25 years. Change in fat percentage and breast development were assessed.
After 12 months of hormone treatment, estrone concentration was 187 pmol/L (95% CI, 153-220) in transdermal and 1516 pmol/L (95% CI, 1284-1748) in oral estradiol users. Fat percentage increased by 1.2% (interquartile range [IQR], 0.3-4.8) in transdermal and 4.6% (IQR, 2.5-5.9) in oral estradiol users. This was not associated with estrone concentrations in transdermal (+4.4% (95% CI, -4.0 to 13) per 100 pmol/L increase in estrone concentration) nor in oral estradiol users (-0.7% [95% CI, -1.7 to 0.3]). Breast volume increased by 69 mL (IQR, 58-134) in transdermal and 62 mL (IQR, 32-95) in oral estradiol users. This was not associated with estrone concentrations in transdermal (+14% [95% CI, -49 to 156] per 100 pmol/L increase in estrone concentration) nor oral estradiol users (+11% [95% CI -14 to 43]).
Change in fat percentage and breast development in trans women were not associated with estrone concentrations nor with administration route. Therefore, measurement of estrone concentrations does not have a place in the monitoring of feminization in trans women.
在跨性别女性中，激素治疗会诱导女性化；然而，每个人的女性化程度因人而异。一个可能的影响因素是雌酮，一种较弱的雌激素，会干扰雌激素受体。
我们评估雌酮是否参与了激素治疗诱导的女性化。
这是一项前瞻性队列研究，随访时间为 1 年，纳入了 2017 年 7 月至 2019 年 12 月在性别认同诊所开始接受性别肯定激素治疗的 212 名成年跨性别女性，中位年龄 25 岁。评估脂肪百分比和乳房发育的变化。
在接受 12 个月的激素治疗后，经皮雌酮浓度为 187pmol/L（95%CI，153-220），口服雌二醇使用者为 1516pmol/L（95%CI，1284-1748）。经皮组的脂肪百分比增加了 1.2%（IQR，0.3-4.8），口服组增加了 4.6%（IQR，2.5-5.9）。这与经皮雌酮浓度的增加无关（每增加 100pmol/L 雌酮浓度增加 4.4%（95%CI，-4.0 至 13）），也与口服雌二醇使用者无关（-0.7%（95%CI，-1.7 至 0.3））。经皮组乳房体积增加了 69mL（IQR，58-134），口服组增加了 62mL（IQR，32-95）。这与经皮雌酮浓度的增加无关（每增加 100pmol/L 雌酮浓度增加 14%（95%CI，-49 至 156）），也与口服雌二醇使用者无关（增加 11%（95%CI，-14 至 43））。
跨性别女性的脂肪百分比和乳房发育变化与雌酮浓度或给药途径无关。因此，测量雌酮浓度在监测跨性别女性的女性化方面没有作用。
